Showing results (331-340 of 395) with videos related to
Sort By:
Pageof 40
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2007
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98Alan S Coates, Aparna Keshaviah, Beat Thürlimann, et al.Journal of the National Cancer Institute|March 8, 2012
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialMeredith M Regan, Brian Leyland-Jones, Mark Bouzyk, et al.Breast Cancer Research and Treatment|September 5, 2009
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trialEvandro de Azambuja, Worta McCaskill-Stevens, Prudence Francis, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 8, 2013
Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trialC Oakman, P A Francis, J Crown, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 11, 2014
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01)Evandro de Azambuja, Marion J Procter, Dirk J van Veldhuisen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2007
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trialThomas M Suter, Marion Procter, Dirk J van Veldhuisen, et al.British Journal of Cancer|September 17, 2014
The AURORA initiative for metastatic breast cancerD Zardavas, M Maetens, A Irrthum, et al.Cancer|December 8, 2020
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trialJose P Leone, Bernard F Cole, Meredith M Regan, et al.The Lancet. Oncology|June 21, 2015
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trialsJürg Bernhard, Weixiu Luo, Karin Ribi, et al.Cancer|March 26, 2003
Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International Breast Cancer Study Group Trial VVito J Spataro, Heather Litman, Giuseppe Viale, et al.Pageof 40